Immunotherapy
From the Journals
Hyperprogression on immunotherapy: When outcomes are much worse
News from the FDA/CDC
FDA panel votes against 2 cancer indications but backs 4 of 6
At a 3-day meeting, an FDA advisory group considered the accelerated approvals of six cancer indications for three immunotherapies.
News from the FDA/CDC
To stay: Two more cancer indications with ‘dangling approvals’
Conference Coverage
Allo-HSCT plus monoclonal antibody treatment can improve survival in patients with r/r B-ALL
Conference Coverage
Checkpoint inhibitor–induced rheumatic complications often arise late
Rheumatologic adverse events associated with immune checkpoint inhibitors can happen later in the course of treatment but also can continue after...
From the Journals
Checkpoint inhibitors’ ‘big picture’ safety shown with preexisting autoimmune diseases
A Dutch nationwide study in melanoma patients found relative safety of immune checkpoint inhibitors for grade 3 immune-related AEs but does not...
Clinical Insights
How should we evaluate the benefit of immunotherapy combinations?
Conference Coverage
Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest
Cancer patients treated with immune checkpoint inhibitors are not significantly more likely to develop or die from COVID-19, two studies suggest...
From the Journals
Real-world results with checkpoint inhibitors found inferior to trial results
Data suggest real-world survival is worse than survival in clinical trials.
Conference Coverage
Lower BP and better tumor control with drug combo?
Conference Coverage
Lenvatinib combo may offer hope after immunotherapy in melanoma